Crystal structures of 11β-hydroxysteroid dehydrogenase type 1 and their use in drug discovery

Future Medicinal Chemistry

Volumn 3, Issue 3, 2011, Pages 367-390

  Thomas, Mark P ^a   Potter, Barry V L ^a  

^a University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; HYDROCORTISONE; INCB 13739; LIGAND; METFORMIN; OXIDOREDUCTASE INHIBITOR; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

CORTICOSTEROID BLOOD LEVEL; CRYSTAL STRUCTURE; DRUG DEVELOPMENT; DRUG STRUCTURE; DRUG SYNTHESIS; GENE SEQUENCE; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; ENZYME INHIBITORS; GLUTAMATE DEHYDROGENASE (NADP+); GUINEA PIGS; HUMANS; HYDROCORTISONE; HYDROGEN BONDING; LIGANDS; METABOLIC SYNDROME X; MICE; MODELS, MOLECULAR; PROTEIN CONFORMATION; RATS;

EID: 79953235168     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.282     Document Type: Review

References (58)

1. Morton NM. Obesity and corticosteroids: 11β-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol. Cell. Endocrinol. 316, 154-164 (2010). Reviews the evidence that 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a good target for metabolic disease intervention.
2. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 89, 2595-2600 (2004). (Pubitemid 38766337)
3. Tomlinson JW, Walker EA, Bujalska IJ et al. 11β-hydroxysteroid dehydrogenase type 1: A tissue-specific regulator of glucocorticoid response. Endocrine Rev. 25, 831-866 (2004). (Pubitemid 39366049)
4. Walker BR. Cortisol - cause and cure for metabolic syndrome? Diabet. Med. 23, 1281-1288 (2006). (Pubitemid 44787789)
5. Friedman JE, Yun JS, Patel YM, McGrane MM, Hanson RW. Glucocorticoids regulate the induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes. J. Biol. Chem. 268, 12952-12957 (1993). (Pubitemid 23182469)
6. Wang M. The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr. Metab. 2, 3 (2005).
7. Hasselgren P-O. Glucocorticoids and muscle catabolism. Curr. Opin. Clin. Nutr. Metab. Care 2, 201-205 (1999). (Pubitemid 129627818)
8. Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing's syndrome: A consensus statement. J. Clin. Endocrinol. Metab. 88, 5593-5602 (2003). (Pubitemid 38033020)
9. Wamil M, Seckl JR. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov. Today 12, 504-520 (2007). (Pubitemid 47031664)
10. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JMC. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 33, 1364-1368 (1999). (Pubitemid 29282655)
11. Stewart PM, Whorwood CB. 11β-hydroxysteroid dehydrogenase activity and corticosteroid hormone action. Steroids 59, 90-95 (1994). (Pubitemid 24080364)
12. Oppermann UCT, Persson B, Jörnvall H.The 11β-hydroxysteroid dehydrogenase system, a determinant of glucocorticoid and mineralocorticoid action: Function, gene organization and protein structures of 11β-hydroxysteroid dehydrogenase isoforms. Eur. J. Biochem. 249, 355-360 (1997).
13. Seckl JR, Walker BR. 11β-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology 142, 1371-1376 (2001). (Pubitemid 32299662)
14. Stewart PM, Valentino R, Wallace AM, Burt D, Shackleton CHL, Edwards CRW. Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 330, 821-824 (1987).
15. Agarwal AK, Mune T, Monder C, White PC. NAD+-dependent isoform of 11β-hydroxysteroid dehydrogenase. J. Biol. Chem. 269, 25959-25962 (1994).
16. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54, 1023-1031 (2005). (Pubitemid 40446315)
17. Morton NM, Paterson JM, Masuzaki H et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53, 931-938 (2004). (Pubitemid 38436604)
18. Kotelevtsev Y, Holmes MC, Burchell A et al. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. USA 94, 14924-14929 (1997). (Pubitemid 28041476)
19. Paterson JM, Morton NM, Fievet C et al. Metabolic syndrome without obesity: Hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. USA 101, 7088-7093 (2004). (Pubitemid 38596447)
20. Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 294, 2166-2170 (2001). (Pubitemid 33150673)
21. Gathercole LL, Stewart PM. Targeting the prereceptor metabolism of cortisol as a novel therapy in obesity and diabetes. J. Steroid Biochem. Molec. Biol. 122, 21-27 (2010). Reviews the role of cortisol in disease as well as the reports of in vivo pharmacological inhibition of 11β-HSD1.
22. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR. Carbenoxolone increases hepatic insulin sensitivity in man: A novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J. Clin. Endocrinol. Metab. 80, 3155-3159 (1995).
23. Rosenstock J, Banarer S, Fonseca VA et al. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with Type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33, 1516-1522 (2010).
24. Webster SP, Pallin TD. 11β-hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents. Expert Opin. Ther. Patents 17, 1407-1422 (2007). Reviews the development of 11β-HSD1 inhibitors.
25. Hughes KA, Webster SP, Walker BR. 11-b-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity. Expert Opin. Investig. Drugs 17, 481-496 (2008). Reviews the development of 11β-HSD1 inhibitors. (Pubitemid 351578167)
26. Su X, Vicker N, Potter BVL. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Prog. Med. Chem. 46, 29-130 (2008). Reviews the development of 11β-HSD1 inhibitors.
27. Boyle CD, Kowalski TJ. 11β-hydroxysteroid dehydrogenase type 1 inhibitors: A review of recent patents. Expert Opin. Ther. Patents 19, 801-825 (2009). Reviews the development of 11β-HSD1 inhibitors.
28. Rohde JJ, Pliushchev MA, Sorensen BK et al. Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11β-hydroxysteroid dehydrogenase type 1 inhibitors. J. Med. Chem. 50, 149-164 (2007). (Pubitemid 46105507)
29. Zhu Y, Olson SH, Graham D et al. Phenylcyclobutyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett. 18, 3412-3416 (2008). (Pubitemid 351718311)
30. Siu M, Johnson TO, Wang Y et al. N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275. Bioorg. Med. Chem. Lett. 19, 3493-3497 (2009).
31. Véniant MM, Hale C, Hungate RW et al. Discovery of a potent, orally active 11β-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: Identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2- ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221). J. Med. Chem. 53, 4481-4487 (2010).
32. Su X, Pradaux-Caggiano F, Thomas MP et al. Discovery of adamantyl ethanone derivatives as potent 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) inhibitors. ChemMedChem 5, 1577-1593 (2010).
33. Holmes MC, Carter RN, Noble J et al. 11β-hydroxysteroid dehydrogenase type 1 expression is increased in the aged mouse hippocampus and parietal cortex and causes memory impairments. J. Neurosci. 30, 6916-6920 (2010).
34. Sooy K, Webster SP, Noble J et al. Partial deficiency or short-term inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves cognitive function in aging mice. J. Neurosci. 30, 13867-13872 (2010).
35. Hosfield DJ, Wu Y, Skene RJ et al. Conformational flexibility in crystal structures of human 11β-hydroxysteroid dehydrogenase type 1 provide insights into glucocorticoid interconversion and enzyme regulation. J. Biol. Chem. 280, 4639-4648 (2005). References [35-52] describe the crystal structures that are the subject of this review. (Pubitemid 40288633)
36. Sorensen B, Winn M, Rohde J et al. Adamantane sulfone and sulphonamide 11-b-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 17, 527-532 (2007). (Pubitemid 46084906)
37. Patel JR, Shuai Q, Dinges J et al. Discovery of adamantane ethers as inhibitors of 11β-HSD-1: Synthesis and biological evaluation. Bioorg. Med. Chem. Lett. 17, 750-755 (2007). (Pubitemid 46108559)
38. Yuan C, St. Jean DJ Jr, Liu Q et al. The discovery of 2-anilinothiazolones as 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 17, 6056-6061 (2007).
39. Johansson L, Fotsch C, Bartberger MD et al. 2-amino-1,3-thiazol-4(5H)- ones as potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitors: Enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57BI/6 mice. J. Med. Chem. 51, 2933-2943 (2008). (Pubitemid 351706022)
40. Hale C, Véniant M, Wang Z et al. Structural characterization and pharmacodynamic effects of an orally active 11β-hydroxysteroid dehydrogenase type 1 inhibitor. Chem. Biol. Drug Des. 71, 36-44 (2008).
41. Wang H, Ruan Z, Li JJ et al. Pyridine amides as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett. 18, 3168-3172 (2008). (Pubitemid 351721009)
42. Sun D, Wang Z, Di Y et al. Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Bioorg. Med. Chem. Lett. 18, 3513-3516 (2008). (Pubitemid 351787572)
43. Julian LD, Wang Z, Bostick T et al. Discovery of novel, potent benzamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model. J. Med. Chem. 51, 3953-3960 (2008). (Pubitemid 351956523)
44. Tu H, Powers JP, Liu J et al. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. 16, 8922-8931 (2008).
45. Fotsch C, Bartberger MD, Bercot EA et al. Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11β-hydroxysteroid dehydrogenase type 1 inhibitors: Reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic model. J. Med. Chem. 51, 7953-7967 (2008).
46. McMinn DL, Rew Y, Sudom A et al. Optimization of novel di-substituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 19, 1446-1450 (2009).
47. Rew Y, McMinn DL, Wang Z et al. Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 19, 1797-1801 (2009).
48. Wan Z-K, Chenail E, Xiang J et al. Efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitors in the diet-induced obesity mouse model. J. Med. Chem. 52, 5449-5461 (2009).
49. Zhang J, Osslund TD, Plant MH et al. Crystal structure of murine 11β-hydroxysteroid dehydrogenase 1: An important therapeutic target for diabetes. Biochemistry 44, 6948-6957 (2005). (Pubitemid 40632413)
50. Ogg D, Elleby B, Norström C et al. The crystal structure of guinea pig 11β-hydroxysteroid dehydrogenase type 1 provides a model for enzyme-lipid bilayer interactions. J. Biol. Chem. 280, 3789-3794 (2005). (Pubitemid 40227484)
51. Lawson AJ, Walker EA, White SA, Dafforn TR, Stewart PM, Ride JP. Mutations of key hydrophobic surface residues of 11β-hydroxysteroid dehydrogenase type 1 increase solubility and monodispersity in a bacterial expression system. Protein Sci. 18, 1552-1563 (2009).
52. Cheng H, Hoffman J, Le P et al. The development and SAR of pyrrolidine carboxamide 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 20, 2897-2902 (2010).
53. Wang Z, Wang M. Structure and inhibitor binding mechanisms of 11β-hydroxysteroid dehydrogenase type 1. Curr. Chem. Biol. 3, 159-170 (2009) Reviews the structures of 11β-HSD1 using a different approach from that adopted in this article, with which it is usefully read in conjunction.
54. Rao ST, Rossmann MG. Comparison of super-secondary structures in proteins. J. Mol. Biol. 76, 241-256 (1973).
55. Hult M, Shafqat N, Elleby B et al. Active site variability of type 1 11β-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons. Mol. Cell. Endocrinol. 248, 26-33 (2006).
56. Xiang J, Wan ZK, Li HQ et al. Piperazine sulfonamides as potent, selective, and orally available 11β-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyper insulinemia model. J. Med. Chem. 51, 4068-4071 (2008). (Pubitemid 352032433)
57. Sun D, Wang Z, Caille S et al. Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 21, 405-410 (2011).
58. Kabsch W, Sander C. Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577-2637 (1983).